Trials / Completed
CompletedNCT03687736
Subject Satisfaction With AbobutulinumtoxinA Treatment
A Multicenter, Open-Label, Interventional Study to Evaluate Subject Satisfaction of AbobutulinumtoxinA Treatments in Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
Detailed description
Following signature of informed consent and the screening process, eligible subjects were treated at the Baseline visit (Day 0) with abobotulinumtoxinA in the glabellar region. Subjects were re-treated at the Month 6 visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AbobotulinumtoxinA | AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6 |
Timeline
- Start date
- 2018-10-02
- Primary completion
- 2019-11-07
- Completion
- 2019-12-04
- First posted
- 2018-09-27
- Last updated
- 2022-08-26
- Results posted
- 2020-03-18
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03687736. Inclusion in this directory is not an endorsement.